

Theodosios D Filippatos

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3215536/theodosios-d-filippatos-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119
papers

3,763
citations

36
h-index

53
g-index

138
ext. papers

4,313
ext. citations

3.6
avg, IF

5.66
L-index

#	Paper	IF	Citations
119	ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. <i>Current Atherosclerosis Reports</i> , 2021 , 23, 20	6	5
118	Sodium-Glucose Cotransporter-2 Inhibitors and Protection Against stroke in Patients with type 2 Diabetes and Impaired Renal Function: A Systematic Review and Meta-Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021 , 30, 105708	2.8	4
117	Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, "Prediabetes," Diabetes and Atherosclerosis. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	4
116	The renin-angiotensin-aldosterone system as a link between obesity and coronavirus disease 2019 severity. <i>Obesity Reviews</i> , 2020 , 21, e13077	10.6	16
115	Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. <i>Clinical Pharmacology: Advances and Applications</i> , 2019 , 11, 133-143	1.5	6
114	Emerging Fixed-Dose Combination Treatments for Hyperlipidemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019 , 24, 315-322	2.6	11
113	Effects of Angiopoietin-Like 3 on Triglyceride Regulation, Glucose Homeostasis, and Diabetes. <i>Disease Markers</i> , 2019 , 2019, 6578327	3.2	21
112	Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects. <i>Current Vascular Pharmacology</i> , 2019 , 17, 332-340	3.3	5
111	SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. <i>Postgraduate Medicine</i> , 2019 , 131, 82-88	3.7	44
110	Apolipoprotein CIII and diabetes. Is there a link?. <i>Diabetes/Metabolism Research and Reviews</i> , 2019 , 35, e3118	7.5	8
109	Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia	1.9	48
108	Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directions. <i>Journal of Hypertension</i> , 2018 , 36, 1441-1455	1.9	26
107	Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic Trials. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018 , 23, 187-191	2.6	2
106	Gitelman syndrome: an analysis of the underlying pathophysiologic mechanisms of acid-base and electrolyte abnormalities. <i>International Urology and Nephrology</i> , 2018 , 50, 91-96	2.3	13
105	SGLT2 inhibitors: are they safe?. <i>Postgraduate Medicine</i> , 2018 , 130, 72-82	3.7	36
104	SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2018 , 12, 59-63	8.9	37
103	Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018 , 23, 3-12	2.6	20

102	Pharmacological management of hyponatremia. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1337-1344		4
101	SGLT2 inhibitors and the kidney: Effects and mechanisms. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2018 , 12, 1117-1123	8.9	26
100	Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 117-125	5.5	4
99	Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?. <i>Current Opinion in Lipidology</i> , 2018 , 29, 333-339	4.4	15
98	SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 1113-1121	5.5	17
97	Phosphate imbalance in patients with heart failure. <i>Heart Failure Reviews</i> , 2017 , 22, 349-356	5	12
96	Serum osmolal gap in clinical practice: usefulness and limitations. <i>Postgraduate Medicine</i> , 2017 , 129, 456-459	3.7	11
95	Non-hemorrhage-related adverse effects of rivaroxaban. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2017 , 2, e108-e112	0.9	11
94	Pathophysiology of Diabetic Dyslipidaemia. <i>Current Vascular Pharmacology</i> , 2017 , 15, 566-575	3.3	14
93	Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition. <i>Current Vascular Pharmacology</i> , 2017 , 15, 96-102	3.3	18
92	Effects of increased body weight and short-term weight loss on serum PCSK9 levels - a prospective pilot study. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2017 , 2, e46-e51	0.9	9
91	Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 1121-1132	4.1	12
90	Modeling anthropometric indices in relation to 10-year (2002-2012) incidence of cardiovascular disease, among apparently healthy individuals: The ATTICA study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017 , 11 Suppl 2, S789-S795	8.9	3
89	Use of intravenous fluids/solutions: a narrative review. <i>Current Medical Research and Opinion</i> , 2017 , 33, 459-471	2.5	13
88	Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 399-408	5.5	15
87	MANAGEMENT OF ENDOCRINE DISEASE: Hypothyroidism-associated hyponatremia: mechanisms, implications and treatment. <i>European Journal of Endocrinology</i> , 2017 , 176, R15-R20	6.5	26
86	Pharmacological management of diabetic dyslipidemia. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 187-200	3.8	21
85	Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?. <i>Diseases (Basel, Switzerland)</i> , 2017 , 5,	4.4	12

84	Hyponatremia in the elderly: challenges and solutions. <i>Clinical Interventions in Aging</i> , 2017 , 12, 1957-1965		49
83	Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1581-3	4	23
82	Hyponatremia in patients with liver diseases: not just a cirrhosis-induced hemodynamic compromise. <i>Hepatology International</i> , 2016 , 10, 762-72	8.8	20
81	Evaluation and treatment of hypernatremia: a practical guide for physicians. <i>Postgraduate Medicine</i> , 2016 , 128, 299-306	3.7	13
80	The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 559-69	4.1	13
79	Electrolyte disorders associated with the use of anticancer drugs. <i>European Journal of Pharmacology</i> , 2016 , 777, 78-87	5.3	48
78	Ten common pitfalls in the evaluation of patients with hyponatremia. <i>European Journal of Internal Medicine</i> , 2016 , 29, 22-5	3.9	26
77	Effects of ezetimibe/simvastatin combination on metabolic parameters. <i>International Journal of Cardiology</i> , 2016 , 202, 273-4	3.2	7
76	Thiazide-associated hyponatremia in the elderly: what the clinician needs to know. <i>Journal of Geriatric Cardiology</i> , 2016 , 13, 175-82	1.7	25
75	Mediterranean Diet and 10-year (2002-2012) Incidence of Diabetes and Cardiovascular Disease in Participants with Prediabetes: The ATTICA study. <i>Review of Diabetic Studies</i> , 2016 , 13, 226-235	3.6	26
74	Pitavastatin and carbohydrate metabolism: what is the evidence?. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 955-60	3.8	7
73	Ten pitfalls in the proper management of patients with hyponatremia. <i>Postgraduate Medicine</i> , 2016 , 128, 516-22	3.7	11
72	Cholesteryl ester transfer protein inhibitors: challenges and perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 953-62	2.5	22
71	Safety considerations with fenofibrate/simvastatin combination. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 1481-93	4.1	18
70	Correction of hypovolemia with crystalloid fluids: Individualizing infusion therapy. <i>Postgraduate Medicine</i> , 2015 , 127, 405-12	3.7	23
69	Current lipid-modifying agents. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1117-8	4	4
68	Dapagliflozin in patients with type 2 diabetes mellitus. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2015 , 6, 29-41	4.5	18
67	Treatment of hyponatremia: the role of lixivaptan. <i>Expert Review of Clinical Pharmacology</i> , 2014 , 7, 431-438	4.18	12

66	Adverse Effects of GLP-1 Receptor Agonists. <i>Review of Diabetic Studies</i> , 2014 , 11, 202-30	3.6	119
65	The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 787-812	5.5	42
64	Recommendations for severe hypertriglyceridemia treatment, are there new strategies?. <i>Current Vascular Pharmacology</i> , 2014 , 12, 598-616	3.3	11
63	Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A _{II} in subjects with prediabetes. <i>Lipids</i> , 2013 , 48, 547-55	1.6	24
62	Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013 , 23, 330-6	4.5	15
61	Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study. <i>Scandinavian Journal of Rheumatology</i> , 2013 , 42, 169-75	1.9	22
60	Effects of glucagon-like peptide-1 receptor agonists on renal function. <i>World Journal of Diabetes</i> , 2013 , 4, 190-201	4.7	47
59	Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?. <i>Review of Diabetic Studies</i> , 2013 , 10, 171-90	3.6	25
58	Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study. <i>Archives of Medical Science</i> , 2013 , 9, 788-95	2.9	19
57	Hyponatremia in patients with heart failure. <i>World Journal of Cardiology</i> , 2013 , 5, 317-28	2.1	43
56	High density lipoprotein and cardiovascular diseases. <i>World Journal of Cardiology</i> , 2013 , 5, 210-4	2.1	15
55	A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. <i>Metabolism: Clinical and Experimental</i> , 2012 , 61, 906-21	12.7	83
54	A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. <i>Cardiovascular Drugs and Therapy</i> , 2012 , 26, 245-55	3.9	16
53	High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. <i>Lipids</i> , 2011 , 46, 521-8	1.6	20
52	Leptospirosis is associated with markedly increased triglycerides and small dense low-density lipoprotein and decreased high-density lipoprotein. <i>Lipids</i> , 2011 , 46, 953-60	1.6	21
51	The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2605-11	4	24
50	Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1945-58	4	21
49	Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. <i>Expert Review of Cardiovascular Therapy</i> , 2011 , 9, 355-66	2.5	16

48	Role of ezetimibe in non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2011 , 3, 265-7	3.4	15
47	Visfatin/PBEF and atherosclerosis-related diseases. <i>Current Vascular Pharmacology</i> , 2010 , 8, 12-28	3.3	51
46	Review article: effects of plant sterols and stanols beyond low-density lipoprotein cholesterol lowering. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010 , 15, 120-34	2.6	43
45	Plasma triglyceride levels and body mass index values are the most important determinants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia. <i>Atherosclerosis</i> , 2010 , 208, 506-11	3.1	15
44	Combination of fenofibrate with non-statin drug regimens. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3401-16	3.3	18
43	Obesity and arterial compliance alterations. <i>Current Vascular Pharmacology</i> , 2010 , 8, 155-68	3.3	49
42	The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. <i>Lipids</i> , 2010 , 45, 445-50	1.6	22
41	Combination drug treatment in obese diabetic patients. <i>World Journal of Diabetes</i> , 2010 , 1, 8-11	4.7	10
40	Combination drug treatment in patients with non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2010 , 2, 139-42	3.4	18
39	Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2009 , 14, 5-13	2.6	27
38	Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors. <i>Clinical Lipidology</i> , 2009 , 4, 331-341		9
37	Lipid-lowering drugs acting at the level of the gastrointestinal tract. <i>Current Pharmaceutical Design</i> , 2009 , 15, 490-516	3.3	41
36	Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. <i>Lipids</i> , 2009 , 44, 9-16	1.6	63
35	Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis. <i>Fundamental and Clinical Pharmacology</i> , 2009 , 23, 595-600	3.1	29
34	Effects of hormonal treatment on lipids in patients with cancer. <i>Cancer Treatment Reviews</i> , 2009 , 35, 175-84	14.4	41
33	The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. <i>Diabetes, Obesity and Metabolism</i> , 2008 , 10, 476-83	6.7	52
32	Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. <i>European Journal of Pharmacology</i> , 2008 , 578, 249-52	5.3	25
31	Orlistat-associated adverse effects and drug interactions: a critical review. <i>Drug Safety</i> , 2008 , 31, 53-65	5.1	217

30	Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. <i>Journal of Clinical Lipidology</i> , 2008 , 2, 279-84	4.9	18
29	Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 1629-39	4	14
28	Treatment of hyperlipidaemia with fenofibrate and related fibrates. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1599-614	5.9	45
27	Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008 , 18, 207-10	4.5	25
26	Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008 , 18, 477-82	4.5	35
25	The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. <i>Current Medical Research and Opinion</i> , 2008 , 24, 1919-29	2.5	59
24	Statins and heart failure. <i>Angiology</i> , 2008 , 59, 58S-61S	2.1	9
23	The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 3151-8	4	31
22	Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 1829-37	4	16
21	Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 2741-50	4	12
20	Increased plasma visfatin levels in subjects with the metabolic syndrome. <i>European Journal of Clinical Investigation</i> , 2008 , 38, 71-2	4.6	60
19	Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women. <i>Diabetes/Metabolism Research and Reviews</i> , 2008 , 24, 223-30	7.5	9
18	Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. <i>Current Medical Research and Opinion</i> , 2007 , 23, 1169-76	2.5	88
17	Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. <i>Journal of Endocrinological Investigation</i> , 2007 , 30, 323-6	5.2	97
16	Excess body weight and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. <i>European Journal of Neurology</i> , 2007 , 14, 762-9	6	15
15	A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. <i>Clinical Therapeutics</i> , 2007 , 29, 1403-14	3.5	45
14	The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. <i>Atherosclerosis</i> , 2007 , 193, 428-37	3.1	82
13	Statin-associated adverse effects beyond muscle and liver toxicity. <i>Atherosclerosis</i> , 2007 , 195, 7-16	3.1	86

12	The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. <i>Lipids</i> , 2006 , 41, 647-54	1.6	66
11	LDL cholesterol estimation in patients with the metabolic syndrome. <i>Lipids in Health and Disease</i> , 2006 , 5, 8	4.4	24
10	Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. <i>Atherosclerosis</i> , 2006 , 187, 170-6	3.1	34
9	Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATORvastatin and ROSuvastatin (the ATOROS study). <i>Current Medical Research and Opinion</i> , 2006 , 22, 1123-31	2.5	55
8	Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. <i>Metabolism: Clinical and Experimental</i> , 2006 , 55, 885-91	12.7	64
7	Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2006 , 33, 921-3	4.1	68
6	Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. <i>Current Medical Research and Opinion</i> , 2005 , 21, 1997-2006	2.5	90
5	The effects of orlistat on metabolic parameters and other cardiovascular risk factors. <i>Diabetes and Metabolism</i> , 2005 , 31, 15-22	5.4	59
4	A review of the metabolic effects of sibutramine. <i>Current Medical Research and Opinion</i> , 2005 , 21, 457-68	2.5	85
3	Alterations in electrolyte equilibrium in patients with acute leukemia. <i>European Journal of Haematology</i> , 2005 , 75, 449-60	3.8	37
2	Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. <i>Clinical Chemistry</i> , 2005 , 51, 2264-73	5.5	146
1	Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering?. <i>Angiology</i> , 2005 , 56, 585-92	2.1	16